

## Novavax, Inc. (NVAX)

**\$6.47** (Stock Price as of 11/21/2025)

Price Target (6-12 Months): **\$9.00**

Long Term: 6-12 Months

**Zacks Recommendation:**

**Neutral**

(Since: 02/25/25)

Prior Recommendation: Outperform

Short Term: 1-3 Months

**Zacks Rank: (1-5)**

**3-Hold**

Zacks Style Scores:

VGM: D

Value: C

Growth: D

Momentum: C

## Summary

Despite being one of the few companies with a COVID-19 vaccine, Novavax, unlike Pfizer and Moderna, could not reap the benefits of the pandemic. Nevertheless, the deal with Sanofi could help offset some of the setbacks; it provides the company with funds for pipeline development. Novavax has advanced the COVID/flu combination vaccine to late-stage development, which could be a game-changer for the stock. It is also advancing several preclinical programs, including one on H5N1 bird flu. Novavax started multiple cost-reduction plans to control its cash burn, which can extend the existing cash runway to support its operations. Any potential development/regulatory setback can hurt the stock. Shares have underperformed the industry year to date. Estimate movements have been mixed ahead of Q3 results. Novavax reported impressive earnings surprises in recent quarters.


## Price, Consensus & Surprise<sup>(1)</sup>



## Data Overview

|                            |                                                   |
|----------------------------|---------------------------------------------------|
| 52 Week High-Low           | \$11.55 - \$5.01                                  |
| 20 Day Average Volume (sh) | 4,369,491                                         |
| Market Cap                 | \$1.1 B                                           |
| YTD Price Change           | -19.5%                                            |
| Beta                       | 2.69                                              |
| Dividend / Div Yld         | \$0.00 / 0.0%                                     |
| Industry                   | <a href="#">Medical - Biomedical and Genetics</a> |
| Zacks Industry Rank        | Top 38% (93 out of 243)                           |

## Sales and EPS Growth Rates (Y/Y %)<sup>(2)</sup>



|                           |            |
|---------------------------|------------|
| Last EPS Surprise         | 42.6%      |
| Last Sales Surprise       | 77.9%      |
| EPS F1 Est- 4 week change | -0.4%      |
| Expected Report Date      | 02/26/2026 |
| Earnings ESP              | -23.6%     |

## Sales Estimates (millions of \$)<sup>(2)</sup>

|      | Q1    | Q2    | Q3    | Q4    | Annual* |
|------|-------|-------|-------|-------|---------|
| 2026 | 38 E  | 43 E  | 175 E | 76 E  | 333 E   |
| 2025 | 667 A | 239 A | 70 A  | 129 E | 1,070 E |
| 2024 | 94 A  | 415 A | 85 A  | 88 A  | 682 A   |

## EPS Estimates<sup>(2)</sup>

|      | Q1      | Q2      | Q3      | Q4      | Annual* |
|------|---------|---------|---------|---------|---------|
| 2026 | -0.29 E | -0.25 E | 0.38 E  | -0.07 E | -0.24 E |
| 2025 | 2.93 A  | 0.62 A  | -0.62 A | -0.17 E | 2.80 E  |
| 2024 | -1.05 A | 0.99 A  | -0.76 A | -0.51 A | -1.23 A |

\*Quarterly figures may not add up to annual.

(1) The data in the charts and tables, except the estimates, is as of 11/21/2025.

(2) The report's text, the analyst-provided estimates, and the price target are as of 10/23/2025.

## Overview

Gaithersburg, MD-based Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company has also developed proprietary immune-stimulating saponin-based adjuvants, namely Matrix-M, added to the company's vaccines to enhance immune response.



Novavax developed its protein-based COVID-19 vaccine, Nuvaxovid/Covovax, which utilizes the company's proprietary nanoparticle technology. Though this vaccine is approved for use in the United States in individuals aged 65 and above, it comes with restrictions for those aged 12-64. Novavax's vaccine is also approved/authorized for use in multiple markets like Australia, Canada, Europe, India and Indonesia.

In May 2024, the company entered into a multi-billion-dollar partnership with Sanofi. Per the deal terms, Sanofi will gain rights to co-market Nuvaxovid globally, except in certain countries where Novavax has existing partnership agreements. Sanofi also has the sole license to develop and market this vaccine in combination with its influenza vaccine. The deal became effective from Jan. 1, 2025.

Novavax is developing a recombinant quadrivalent seasonal influenza vaccine candidate. It is also evaluating the combination of the influenza vaccine with the COVID-19 vaccine. The company advanced both candidates to late-stage development in December 2024.

To rationalize its manufacturing footprint and reduce costs, the company has undertaken multiple restructuring initiatives. These initiatives have not only helped the company in bringing down its current costs but also reduced current liabilities by about \$2.1 billion over the past three years.

In 2024, the company generated \$682.2 million in total revenues, down 31% year over year.



## Reasons To Buy:

▲ **Solid Partner in Sanofi:** The partnership is a big win for Novavax. As part of this deal, the company received a payment of \$570 million from Sanofi, which includes \$70 million in equity investment. With a pharma giant like Sanofi, which has more experience and an established supply chain for marketing vaccines, Novavax's COVID-19 vaccine would now have access to a wider audience. Novavax is eligible for cost reimbursement by Sanofi for certain R&D costs. The deal also allows both companies to develop their own combined COVID-19-influenza combination vaccines and adjuvanted products at their expense.

The collaboration deal with Sanofi likely breathes new life into the company.

The collaboration deal with Sanofi likely breathes new life for Novavax which had been facing uncertainties in its business. The deal bodes well for Novavax as it provides the company with funds to support its ongoing pipeline programs. Per the deal terms, Novavax is eligible to receive milestone payments of up to \$700 million and royalties on sales of the COVID-19 vaccine from Sanofi. The positive cashflows generated from this deal are a major reason that the company removed its 'going concern' warning.

▲ **Restructuring Initiatives Encouraging:** To extend its existing cash runway and curb cash burn, Novavax initiated a cost reduction plan in May 2023. The company lowered the combined research and development (R&D) and selling, general and administrative (SG&A) expenses by about 60% in 2024 and 30% in 2023 when compared with expenses incurred in 2022. In January 2024, Novavax decided to undertake another cost reduction plan, wherein it will reduce its global workforce by 12%. Through these restructuring measures, it aims to rationalize its manufacturing footprint. The company targets the combined R&D and SG&A expenses to be between \$495 and \$545 million for 2025, \$350 million for 2026 and \$250 million for 2027, indicating a substantial reduction from the \$728 million incurred in 2024. Our model estimates suggest that total operating expenses would decline at a CAGR of nearly 36% over the next three years.

▲ **Progress With Vaccine Pipeline Encouraging:** Following the transfer of commercial responsibilities for its COVID-19 vaccine to Sanofi, Novavax has decided to focus on expanding its pipeline and exploring partnership opportunities for the same.

The company is progressing well with the development of its other vaccine candidates, i.e., stand-alone influenza and COVID-19-influenza combination (CIC) vaccines. In June 2025, Novavax reported data from a phase III study, which showed that both vaccines generated "robust immune responses" across three flu strains (H1N1, H3N2 and B) and the SARS-CoV-2 strain in adults aged 65 and older. Per the company, these responses were similar to those seen with Nuvaxovid and Sanofi's influenza vaccine, Fluzone HD. Novavax intends to use these findings to design another late-stage study, which could potentially support regulatory submissions, if successful.

Novavax is also progressing well with its preclinical pipeline, which includes vaccines for RSV and H5N1 bird flu. It is also advancing core technology for different uses like mucosal vaccination and high-density nanoparticles. The company intends to focus on exploring RSV-combination options and new opportunities in diseases like varicella-zoster virus (shingles) and Clostridium difficile (C. Diff.) colitis. It is also planning to expand into the field of oncology.

▲ **Commercial Opportunities for Matrix-M Adjuvant Encouraging:** An adjuvant is an ingredient in a vaccine that enhances the immune system's response to that vaccine. Novavax has developed its proprietary adjuvant technology, known as Matrix-M, which is designed to work with its nanoparticle vaccines. The company is also exploring commercial opportunities for using its proprietary adjuvant in vaccines produced by other manufacturers.

The University of Oxford used the Matrix-M adjuvant to develop the R21 vaccine for malaria. The technology has been licensed to Serum for commercializing the R21/Matrix-M vaccine. Novavax claims that several partners are also using the technology to develop their malaria vaccines. In 2023, the technology was also licensed to the Bill & Melinda Gates Medical Research Institute and SK bioscience for use in preclinical vaccine research and experiments.

As part of its collaboration deal, Novavax has also provided a non-exclusive license to Sanofi to use the Matrix-M adjuvant technology in other vaccine products. In return, Novavax is entitled to receive a milestone payment of up to \$210 million from Sanofi, plus mid-single-digit royalties.

Novavax has also started developing new Matrix formulations designed to support flexible dosing schedules, enhance vaccine effectiveness and expand into therapeutic areas beyond infectious diseases. These innovations aim to enable targeted treatments and broaden the platform's potential across multiple medical applications.

▲ **Favorable Debt Profile:** As of June 30, 2025, the company's total debt (current and long-term debt) was approximately \$223 million. Cash, cash equivalents and marketable securities totaled \$628 million, which is more than enough to pay off its debts in case of insolvency.

---

## Reasons To Sell:

- ▼ **Lacklustre Performance of COVID-19 Vaccine Sales:** Novavax's first marketed product is its COVID-19 vaccine, which is also the only non-mRNA-based vaccine approved for use in the United States. However, the product launch was delayed by nearly a year due to the postponement of the regulatory filing with the FDA. The FDA filing, which the company was supposed to complete in May 2021, was finalized after multiple delays in January 2022. By the time the FDA authorized the vaccine, most of the population had already been inoculated with mRNA-based vaccines from Pfizer/BioNTech and Moderna. This delayed filing resulted in a significant loss of market share for the company. This was also one of the likely reasons that the company was unable to fully reap the benefits of vaccine sales compared to its peers, such as Moderna, Pfizer, and BioNTech. As the COVID-19 pandemic has ended, the demand for COVID-19 vaccines has declined, leading to Novavax recording minimal sales from its COVID-19 vaccine in 2024.
- ▼ **Stiff Competition:** Novavax's target market is highly competitive. The company faces stiff competition from large-cap pharma giants like GSK, Pfizer and Moderna for both its marketed as well as pipeline vaccines. These companies are far ahead of Novavax in terms of marketing and distribution of their vaccines and have already catered to billions of people across the globe.
- ▼ **Pipeline/Regulatory Setbacks:** In October 2024, the FDA placed a clinical hold on the company's CIC and stand-alone influenza vaccine candidates. This clinical hold was placed after a study participant who took the combo shot as part of a phase II study reported nerve damage. Though the hold was subsequently lifted in November 2024, it delayed the company's plans to start the late-stage study on both vaccines. Such setbacks are detrimental to the company's stock price and growth prospects.

Apart from COVID vaccine, Novavax has no other marketed products. The vaccine faces stiff competition from Pfizer and Moderna's mRNA vaccines.

## Last Earnings Report

### Q2 Earnings & Sales Beat Estimates

Novavax reported second-quarter 2025 EPS of 62 cents, against the Zacks Consensus Estimate of a loss of 7 cents. However, the reported figure declined 37% year over year.

Quarterly revenues totaled \$239 million, down 42% year over year. Yet, the metric beat the Zacks Consensus Estimate of \$118 million.

### Quarter in Detail

Novavax recorded \$11 million in product sales compared with \$23 million in the year-ago period. The reported figure includes a net reversal of \$2 million in sales of its sole marketed product, the COVID-19 vaccine Nuvaxovid, and \$13 million from supply sales, which comprise finished product, adjuvant and other materials sold to licensed partners.

Licensing, royalties and other revenues totaled \$228.5 million, which includes \$175 million recognized as a milestone payment from partner Sanofi. This payment was triggered after the company received full approval from the FDA for Nuvaxovid in May 2025.

In the reported quarter, research and development (R&D) expenses totaled \$79 million, down 26% year over year. The downside was caused by a reduction in overall expenditures relating to COVID-19 vaccine development.

Selling, general and administrative (SG&A) expenses decreased 57% year over year to \$44 million. This downtick was due to several factors, including the transition of lead commercial activities to Sanofi, the elimination of commercial infrastructure and ongoing cost reduction efforts.

As of June 30, 2025, the company had \$628 million in cash and cash equivalents compared with \$747 million as of March 31, 2025. While the \$175 million was recognized in the second quarter, Novavax expects its receipt in Q3.

### 2025 Guidance

The company has raised its adjusted revenue framework and now expects to generate between \$1 billion and \$1.05 billion, implying an increase from the prior projection of \$0.98-\$1.03 billion. This revision is largely due to the receipt of \$20 million for cost reimbursement from Sanofi for a post-marketing commitment (PMC) requested by the FDA on Nuvaxovid later this year.

Novavax also raised its full-year projection for combined R&D and SG&A expenses, which are now expected in the range of \$495-\$545 million (previously: \$475-\$525 million).

Novavax expects the transfers of marketing authorization to Sanofi for the U.S. and EU markets in the fourth quarter of 2025. The completion of these events will trigger an additional \$50 million in combined milestone payments.

**FY Quarter Ending** **12/31/2024**

| Earnings Reporting Date | Nov 06, 2025 |
|-------------------------|--------------|
| Sales Surprise          | 77.85%       |
| EPS Surprise            | 42.59%       |
| Quarterly EPS           | -0.62        |
| Annual EPS (TTM)        | 2.42         |

---

## Recent News

### **Sells Facility for \$60M to Streamline Operations — Oct. 22**

Novavax announced that it has signed a definitive agreement with AstraZeneca to transfer the lease agreement related to one of its Maryland-based locations (700 Quince Orchard Road, Gaithersburg, Maryland). This part is part of the company's strategy to focus on R&D efforts by "retaining the necessary capabilities in the leanest and most cost-effective manner."

Under this transaction, Novavax will be eligible to receive nearly \$60 million. It also expects the transaction to result in future cost savings of \$230 million over 11 years related to both lease expense and facility operating costs.

### **Completes Nuvaxovid EU Marketing Authorization Transfer to Sanofi — Oct. 7**

Novavax announced that it has completed the transfer of the marketing authorization for Nuvaxovid in the EU to Sanofi. This transfer enables Sanofi to take full responsibility for commercial and regulatory activities in the region and also triggers a milestone payment of \$25 million to the company.

### **Broadens Partnership With Sanofi — Sept. 30**

Novavax has amended its existing collaboration and license agreement (CLA) with Sanofi regarding its Matrix-M adjuvant. The revised agreement expands Sanofi's rights to include the use of Matrix-M in its pandemic influenza vaccine candidate program. Under the terms of the amendment, Sanofi is permitted to use Matrix-M in early-stage development of its pandemic influenza vaccine candidates through phase II. Should Sanofi advance a Matrix-M-containing vaccine into late-stage clinical development, the companies will negotiate the applicable license rates and financial terms at that stage.

---

## Valuation

Novavax's shares have risen 5.2% year to date and declined 14.7% over the trailing 12-month period. Stocks in the Zacks sub-industry are up 10.5%, while those in the sector have gained 1.8% in the year-to-date period. In the past year, the Zacks sub-industry and sector have lost 3.2% and 9.1%, respectively.

The S&P 500 Index has risen 15.4% year to date and 18.1% in the past year.

The stock is currently trading at 1.39X trailing 12-month sales per share, which compares to 2.28X for the Zacks sub-industry, 2.50X for the Zacks sector, and 5.98X for the S&P 500 index.

Over the past five years, the stock has traded as low as 0.23X, with a 5-year median of 1.84X. Our Neutral recommendation indicates that the stock will perform in line with the market. Our \$9.00 price target reflects 1.48X trailing 12-month sales per share.

---

## Industry Analysis<sup>(1)</sup> Zacks Industry Rank: Top 38% (93 out of 243)



## Top Peers<sup>(1)</sup>

| Company (Ticker)              | Rec        | Rank |
|-------------------------------|------------|------|
| ANI Pharmaceuticals,...(ANIP) | Outperform | 1    |
| Guardant Health, Inc...(GH)   | Neutral    | 3    |
| HUTCHMED (China) Lim...(HCM)  | Neutral    | 3    |
| Harmony Biosciences ...(HRMY) | Neutral    | 3    |
| Legend Biotech Corpo...(LEGN) | Neutral    | 3    |
| NeoGenomics, Inc. (NEO)       | Neutral    | 3    |
| Pacira BioSciences, ...(PCRX) | Neutral    | 3    |
| Repligen Corporation (RGEN)   | Neutral    | 4    |

## Industry Comparison<sup>(1)</sup> Industry: Medical - Biomedical And Genetics

|                                  | NVAX      | X Industry | S&P 500   | HRMY    | NEO       | PCRX     |
|----------------------------------|-----------|------------|-----------|---------|-----------|----------|
| Zacks Recommendation (Long Term) | Neutral   | -          | -         | Neutral | Neutral   | Neutral  |
| Zacks Rank (Short Term)          | 3         | -          | -         | 3       | 3         | 3        |
| VGM Score                        | D         | -          | -         | A       | D         | B        |
| Market Cap                       | 1.05 B    | 161.66 M   | 37.69 B   | 1.98 B  | 1.49 B    | 991.64 M |
| # of Analysts                    | 7         | 3          | 22        | 6       | 6         | 5        |
| Dividend Yield                   | 0.00%     | 0.00%      | 1.52%     | 0.00%   | 0.00%     | 0.00%    |
| Value Score                      | C         | -          | -         | A       | C         | A        |
| Cash/Price                       | 0.74      | 0.32       | 0.04      | 0.34    | 0.11      | 0.25     |
| EV/EBITDA                        | -4.85     | -1.43      | 14.29     | 6.26    | 1,185.13  | 31.63    |
| PEG Ratio                        | NA        | 1.58       | 2.16      | 0.44    | 2.57      | NA       |
| Price/Book (P/B)                 | NA        | 2.73       | 3.28      | 2.36    | 1.77      | 1.42     |
| Price/Cash Flow (P/CF)           | NA        | 17.92      | 14.45     | 11.64   | 26.17     | 5.34     |
| P/E (F1)                         | 2.31      | 18.52      | 19.75     | 11.01   | 120.84    | 7.97     |
| Price/Sales (P/S)                | 0.99      | 6.52       | 2.99      | 2.39    | 2.09      | 1.38     |
| Earnings Yield                   | 33.08%    | -19.43%    | 5.04%     | 9.09%   | 0.78%     | 12.54%   |
| Debt/Equity                      | -1.57     | 0.00       | 0.57      | 0.18    | 0.41      | 0.52     |
| Cash Flow (\$/share)             | -0.87     | -1.45      | 8.99      | 2.95    | 0.44      | 4.32     |
| Growth Score                     | D         | -          | -         | A       | C         | B        |
| Hist. EPS Growth (3-5 yrs)       | NA%       | 4.20%      | 8.17%     | 13.09%  | NA        | 5.79%    |
| Proj. EPS Growth (F1/F0)         | NA%       | 17.24%     | 8.30%     | 24.30%  | -9.09%    | -9.97%   |
| Curr. Cash Flow Growth           | -72.41%   | -6.22%     | 7.00%     | 10.00%  | 56.49%    | 8.44%    |
| Hist. Cash Flow Growth (3-5 yrs) | -0.74%    | 3.19%      | 7.32%     | 25.67%  | 0.82%     | 22.57%   |
| Current Ratio                    | 2.27      | 4.23       | 1.18      | 3.75    | 3.91      | 5.26     |
| Debt/Capital                     | 85.56%    | 0.00%      | 38.16%    | 15.10%  | 28.94%    | 34.13%   |
| Net Margin                       | 32.10%    | -125.46%   | 12.75%    | 22.50%  | -16.00%   | 2.99%    |
| Return on Equity                 | -217.02%  | -67.49%    | 17.03%    | 24.88%  | -3.36%    | 12.82%   |
| Sales/Assets                     | 0.79      | 0.31       | 0.53      | 0.76    | 0.47      | 0.48     |
| Proj. Sales Growth (F1/F0)       | 56.90%    | 0.00%      | 5.53%     | 20.70%  | 9.70%     | 4.30%    |
| Momentum Score                   | C         | -          | -         | D       | D         | D        |
| Daily Price Chg                  | 4.02%     | 1.34%      | 0.98%     | 2.76%   | 8.30%     | 1.10%    |
| 1 Week Price Chg                 | -7.17%    | 0.00%      | -1.95%    | 0.82%   | 11.03%    | -3.07%   |
| 4 Week Price Chg                 | -24.06%   | -5.02%     | -2.78%    | 13.42%  | 7.59%     | 6.03%    |
| 12 Week Price Chg                | -13.39%   | 0.92%      | 2.21%     | -6.99%  | 30.75%    | -13.57%  |
| 52 Week Price Chg                | -23.61%   | -13.12%    | 10.61%    | 0.70%   | -29.96%   | 31.34%   |
| 20 Day Average Volume            | 4,369,491 | 388,117    | 3,031,286 | 918,615 | 3,062,041 | 740,722  |
| (F1) EPS Est 1 week change       | 0.42%     | 0.00%      | 0.00%     | 0.00%   | 0.20%     | -0.58%   |
| (F1) EPS Est 4 week change       | -0.41%    | 0.00%      | 0.32%     | -1.06%  | 6.01%     | 1.72%    |
| (F1) EPS Est 12 week change      | -9.40%    | 0.99%      | 0.58%     | -1.16%  | 5.84%     | 3.04%    |
| (Q1) EPS Est Mthly Chg           | -7.91%    | 0.00%      | -0.06%    | -23.60% | -9.09%    | 1.90%    |



## Analyst Earnings Model<sup>(2)</sup>

### Novavax, Inc. (NVAX)

In \$MM, except per share data

|                                          | 2018A            | 2019A            | 2020A            | 2021A              | 2022A            | 2023A            | 2024A            | 1 QA           | 2 QA           | 2025E           | 4QE             | FY               | 1QE             | 2QE             | 2026E          | 4QE             | FY              | 2027E          |
|------------------------------------------|------------------|------------------|------------------|--------------------|------------------|------------------|------------------|----------------|----------------|-----------------|-----------------|------------------|-----------------|-----------------|----------------|-----------------|-----------------|----------------|
| FY Ends December 31st                    | Dec-18           | Dec-19           | Dec-20           | Dec-21             | Dec-22           | Dec-23           | Dec-24           | 31-Mar-25      | 30-Jun-25      | 30-Sep-25       | 31-Dec-25       | Dec-25           | 31-Mar-26       | 30-Jun-26       | 30-Sep-26      | 31-Dec-26       | Dec-26          | Dec-27         |
| <b>Income Statement</b>                  |                  |                  |                  |                    |                  |                  |                  |                |                |                 |                 |                  |                 |                 |                |                 |                 |                |
| Total Product Sales                      |                  |                  |                  |                    | \$1,555.0        | \$531.4          | \$190.2          | \$621.7        | \$10.7         | \$13.0          | \$13.0          | \$658.4          | \$6.0           | \$10.0          | \$25.0         | \$38.0          | \$79.0          | \$33.0         |
| YoY % Chng                               |                  |                  |                  |                    |                  | (65.8%)          | (64.2%)          | 592.0%         | (52.5%)        | (66.0%)         | (73.9%)         | 246.1%           | (99.0%)         | (6.8%)          | 92.3%          | 192.3%          | (88.0%)         | (58.2%)        |
| Grants                                   | \$34.3           | \$15.9           | \$453.2          | \$948.7            | \$382.9          | \$427.3          | \$0.0            | \$0.0          | \$0.0          | \$0.0           | \$0.0           | \$0.0            | \$0.0           | \$0.0           | \$0.0          | \$0.0           | \$0.0           | \$0.0          |
| YoY % Chng                               |                  | (33.3%)          | 2,743.8%         | 109.3%             | (59.6%)          | 11.6%            |                  |                |                |                 |                 |                  |                 |                 |                |                 |                 |                |
| License, Royalties & Other               |                  | \$2.7            | \$22.4           | \$197.6            | \$44.0           | \$25.0           | \$492.0          | \$45.0         | \$228.5        | \$22.0          | \$116.0         | \$411.5          | \$32.1          | \$33.2          | \$150.4        | \$37.9          | \$253.6         | \$305.9        |
| YoY % Chng                               |                  |                  | 721.6%           | 782.5%             | (77.7%)          | (43.2%)          | 1,868.4%         | 1,019.1%       | (41.8%)        | (52.5%)         | 201.0%          | (16.4%)          | (28.6%)         | (85.5%)         | 583.6%         | (67.3%)         | (38.4%)         | 20.6%          |
| <b>Total Revenue</b>                     | <b>\$34.3</b>    | <b>\$18.7</b>    | <b>\$475.6</b>   | <b>\$1,146.3</b>   | <b>\$1,981.9</b> | <b>\$983.7</b>   | <b>\$682.2</b>   | <b>\$666.7</b> | <b>\$239.2</b> | <b>\$35.0</b>   | <b>\$129.0</b>  | <b>\$1,069.9</b> | <b>\$38.1</b>   | <b>\$43.2</b>   | <b>\$175.4</b> | <b>\$75.9</b>   | <b>\$332.6</b>  | <b>\$338.9</b> |
| YoY % Chng                               |                  | (45.6%)          | 2,448.5%         | 141.0%             | 72.9%            | (50.4%)          | (30.7%)          | 610.3%         | (42.4%)        | (58.6%)         | 46.1%           | 56.8%            | (94.3%)         | (81.9%)         | 401.1%         | (41.2%)         | (68.9%)         | 1.9%           |
| Cost of Sales                            | \$0.0            | \$0.0            | \$0.0            | \$0.0              | \$902.6          | \$343.8          | \$202.7          | \$14.1         | \$15.3         | \$2.0           | \$1.0           | \$32.4           | \$0.0           | \$0.0           | \$0.0          | \$0.0           | \$0.0           | \$0.0          |
| YoY % Chng                               |                  |                  |                  |                    |                  | (61.9%)          | (41.0%)          | (76.2%)        | (66.9%)        | (96.7%)         | (97.3%)         | (84.0%)          |                 |                 |                |                 |                 |                |
| <b>Gross Profit</b>                      | <b>\$34.3</b>    | <b>\$18.7</b>    | <b>\$475.6</b>   | <b>\$1,146.3</b>   | <b>\$1,079.2</b> | <b>\$639.9</b>   | <b>\$479.4</b>   | <b>\$652.5</b> | <b>\$223.9</b> | <b>\$33.0</b>   | <b>\$128.0</b>  | <b>\$1,037.5</b> | <b>\$38.1</b>   | <b>\$43.2</b>   | <b>\$175.4</b> | <b>\$75.9</b>   | <b>\$332.6</b>  | <b>\$338.9</b> |
| YoY % Chng                               |                  | (45.6%)          | 2,448.5%         | 141.0%             | (5.8%)           | (40.7%)          | (25.1%)          | 1,783.4%       | (39.4%)        | 38.1%           | 147.9%          | 116.4%           | (94.2%)         | (80.7%)         | 431.5%         | (40.7%)         | (67.9%)         | 1.9%           |
| Research & Development                   | \$173.8          | \$113.8          | \$747.0          | \$2,534.5          | \$1,235.3        | \$737.5          | \$391.2          | \$88.9         | \$79.2         | \$88.8          | \$97.9          | \$354.9          | \$60.0          | \$60.5          | \$60.3         | \$60.1          | \$240.8         | \$181.1        |
| YoY % Chng                               |                  | (34.5%)          | 556.2%           | 239.3%             | (51.3%)          | (40.3%)          | (47.0%)          | (4.0%)         | (25.9%)        | 1.9%            | (6.2%)          | (9.3%)           | (32.6%)         | (23.7%)         | (32.1%)        | (28.6%)         | (32.2%)         | (24.8%)        |
| Selling, General & Administrative        | \$34.4           | \$34.4           | \$145.3          | \$298.4            | \$488.7          | \$468.9          | \$337.2          | \$48.1         | \$43.6         | \$38.7          | \$55.5          | \$185.9          | \$27.4          | \$27.2          | \$27.2         | \$27.3          | \$109.1         | \$68.9         |
| YoY % Chng                               |                  | 0.0%             | 322.1%           | 105.4%             | 63.8%            | (4.0%)           | (28.1%)          | (44.6%)        | (56.9%)        | (45.3%)         | (29.1%)         | (44.9%)          | (43.0%)         | (37.6%)         | (29.7%)        | (50.9%)         | (41.3%)         | (36.8%)        |
| <b>Total Operating Expenses</b>          | <b>\$208.2</b>   | <b>\$139.2</b>   | <b>\$892.3</b>   | <b>\$2,832.9</b>   | <b>\$2,626.6</b> | <b>\$1,550.2</b> | <b>\$931.1</b>   | <b>\$151.1</b> | <b>\$138.2</b> | <b>\$129.5</b>  | <b>\$154.5</b>  | <b>\$573.3</b>   | <b>\$87.4</b>   | <b>\$87.7</b>   | <b>\$87.4</b>  | <b>\$87.4</b>   | <b>\$349.9</b>  | <b>\$250.1</b> |
| YoY % Chng                               |                  | (33.1%)          | 540.8%           | 217.5%             | (7.3%)           | (41.0%)          | (39.9%)          | (36.7%)        | (45.7%)        | (40.7%)         | (29.6%)         | (38.4%)          | (42.2%)         | (36.5%)         | (32.5%)        | (43.4%)         | (39.0%)         | (28.5%)        |
| <b>EBITDA</b>                            | <b>(\$165.8)</b> | <b>(\$114.9)</b> | <b>(\$411.8)</b> | <b>(\$1,673.9)</b> | <b>(\$615.7)</b> | <b>(\$525.3)</b> | <b>(\$200.4)</b> | <b>\$52.3</b>  | <b>\$108.6</b> | <b>(\$83.0)</b> | <b>(\$14.9)</b> | <b>\$534.5</b>   | <b>(\$42.9)</b> | <b>(\$38.6)</b> | <b>\$97.3</b>  | <b>(\$3.0)</b>  | <b>\$12.7</b>   | <b>\$112.8</b> |
| YoY % Chng                               |                  | 30.7%            | (259.4%)         | (306.5%)           | 63.2%            | 14.7%            | 61.8%            | 494.8%         | (36.9%)        | 31.5%           | 87.4%           | 366.7%           | (108.2%)        | (135.6%)        | 217.2%         | 79.6%           | (97.6%)         | 785.1%         |
| Depreciation & Amortization              | \$8.2            | \$5.7            | \$4.9            | \$12.7             | \$21.9           | \$41.2           | \$8.5            | \$8.3          | \$7.2          | \$11.4          | \$10.6          | \$37.9           | \$6.3           | \$5.8           | \$9.4          | \$8.5           | \$30.0          | \$23.9         |
| YoY % Chng                               |                  | (30.4%)          | (13.9%)          | 159.2%             | 129.5%           | 41.9%            | 17.6%            | (31.3%)        | (32.3%)        | (9.9%)          | (15.4%)         | (21.8%)          | (24.2%)         | (22.4%)         | (18.0%)        | (20.0%)         | (20.8%)         | (20.4%)        |
| <b>Operating Income (Loss)</b>           | <b>(\$173.9)</b> | <b>(\$120.6)</b> | <b>(\$416.7)</b> | <b>(\$1,686.6)</b> | <b>(\$644.7)</b> | <b>(\$566.5)</b> | <b>(\$248.9)</b> | <b>\$515.5</b> | <b>\$101.1</b> | <b>(\$94.5)</b> | <b>(\$25.5)</b> | <b>\$496.6</b>   | <b>(\$49.3)</b> | <b>(\$44.5)</b> | <b>\$87.9</b>  | <b>(\$11.5)</b> | <b>(\$17.3)</b> | <b>\$88.9</b>  |
| YoY % Chng                               |                  | 30.7%            | (245.6%)         | (304.7%)           | 61.8%            | 12.1%            | 55.9%            | 455.9%         | (37.2%)        | 29.5%           | 80.6%           | 193.1%           | (109.6%)        | (144.0%)        | 193.1%         | 54.9%           | (103.5%)        | 614.3%         |
| Interest Expense, Net                    | \$10.9           | \$12.1           | \$14.1           | \$21.1             | \$19.9           | \$14.4           | \$20.1           | \$5.7          | \$5.5          | \$5.0           | \$6.4           | \$22.6           | \$2.5           | \$2.6           | \$5.2          | \$3.9           | \$14.2          | \$10.5         |
| YoY % Chng                               |                  | 10.6%            | 16.8%            | 49.5%              | (5.9%)           | (27.5%)          | 39.3%            | 39.2%          | 33.2%          | 17.2%           | (15.2%)         | 12.8%            | (56.1%)         | (52.9%)         | 4.0%           | (39.4%)         | (37.4%)         | (25.8%)        |
| Other Income (Expense)                   | \$0.1            | (\$0.0)          | \$12.6           | (\$6.8)            | \$11.0           | \$37.9           | \$40.4           | \$10.1         | \$11.9         | \$2.8           | \$3.0           | \$27.8           | \$1.6           | \$2.1           | \$0.7          | \$2.0           | \$6.4           | \$5.6          |
| YoY % Chng                               |                  | (112.0%)         | 96,953.6%        | (154.3%)           | 260.5%           | 245.5%           | 6.7%             | 175.2%         | 54.0%          | (82.3%)         | (76.9%)         | (31.2%)          | (84.0%)         | (82.2%)         | (76.3%)        | (33.4%)         | (76.9%)         | (13.4%)        |
| Gain on Disposition of Novavax CZ Assets |                  |                  |                  |                    |                  |                  | \$51.9           | \$0.0          | \$0.0          | \$0.0           | \$0.0           | \$0.0            | \$0.0           | \$0.0           | \$0.0          | \$0.0           | \$0.0           | \$0.0          |
| YoY % Chng                               |                  |                  |                  |                    |                  |                  |                  |                |                |                 |                 |                  |                 |                 |                |                 |                 |                |
| <b>Pre-Tax Income (Loss)</b>             | <b>(\$184.7)</b> | <b>(\$132.7)</b> | <b>(\$418.3)</b> | <b>(\$1,714.5)</b> | <b>(\$653.6)</b> | <b>(\$543.0)</b> | <b>(\$176.6)</b> | <b>\$519.8</b> | <b>\$107.5</b> | <b>(\$96.6)</b> | <b>(\$28.9)</b> | <b>\$501.8</b>   | <b>(\$50.2)</b> | <b>(\$44.9)</b> | <b>\$83.4</b>  | <b>(\$13.4)</b> | <b>(\$25.0)</b> | <b>\$83.9</b>  |
| YoY % Chng                               |                  | 28.2%            | (219.2%)         | (309.9%)           | 61.9%            | 16.9%            | 67.5%            | 457.8%         | (34.7%)        | 21.0%           | 60.8%           | 384.1%           | (109.6%)        | (141.8%)        | 186.3%         | 53.7%           | (105.0%)        | 435.1%         |
| Income Tax                               | \$0.0            | \$0.0            | \$0.0            | \$29.2             | \$4.3            | \$2.0            | \$10.9           | \$1.2          | \$0.9          | \$0.0           | \$0.0           | \$2.1            | \$0.0           | \$0.0           | \$8.3          | \$0.0           | \$8.3           | \$44.4         |
| YoY % Chng                               |                  |                  |                  |                    | (85.3%)          | (52.7%)          | 435.9%           | (46.9%)        | (57.1%)        |                 |                 | (80.3%)          |                 |                 |                |                 |                 | 431.9%         |
| Tax Rate                                 | 0.0%             | 0.0%             | 0.0%             | (1.7%)             | (0.7%)           | (0.4%)           | (6.2%)           | 0.2%           | 0.9%           | 0.0%            | 0.0%            | 0.4%             | 0.0%            | 0.0%            | 10.0%          | 0.0%            | (33.3%)         | 52.9%          |
| <b>Net Income (Loss)</b>                 | <b>(\$184.7)</b> | <b>(\$132.7)</b> | <b>(\$418.3)</b> | <b>(\$1,743.8)</b> | <b>(\$657.9)</b> | <b>(\$545.1)</b> | <b>(\$187.5)</b> | <b>\$518.6</b> | <b>\$106.5</b> | <b>(\$96.6)</b> | <b>(\$28.9)</b> | <b>\$499.6</b>   | <b>(\$50.2)</b> | <b>(\$44.9)</b> | <b>\$75.1</b>  | <b>(\$13.4)</b> | <b>(\$33.4)</b> | <b>\$39.5</b>  |
| YoY % Chng                               |                  | 28.2%            | (215.2%)         | (316.9%)           | 62.3%            | 17.2%            | 65.6%            | 451.5%         | (34.4%)        | 20.3%           | 64.4%           | 366.5%           | (109.7%)        | (142.2%)        | 177.7%         | 53.7%           | (106.7%)        | 218.4%         |
| Basic Shares Outstanding                 | 18.5             | 24.1             | 57.6             | 74.4               | 78.2             | 100.8            | 152.2            | 161.0          | 162.0          | 165.8           | 169.6           | 164.6            | 173.4           | 177.2           | 181.0          | 184.8           | 179.1           | 194.3          |
| YoY % Chng                               |                  | 30.4%            | 138.8%           | 29.3%              | 5.1%             | 28.9%            | 51.0%            | 15.1%          | 9.2%           | 3.6%            | 5.9%            | 8.2%             | 7.7%            | 9.4%            | 9.2%           | 9.0%            | 8.8%            | 8.5%           |
| Diluted Shares Outstanding               | 18.5             | 24.1             | 57.6             | 74.4               | 78.2             | 100.8            | 152.2            | 177.6          | 177.2          | 165.8           | 169.6           | 172.6            | 173.4           | 177.2           | 198.0          | 184.8           | 183.4           | 198.6          |
| YoY % Chng                               |                  | 30.4%            | 138.8%           | 29.3%              | 5.1%             | 28.9%            | 51.0%            | 27.0%          | 6.8%           | 3.6%            | 5.9%            | 13.4%            | (2.4%)          | 0.0%            | 19.4%          | 9.0%            | 6.3%            | 8.3%           |
| <b>Basic EPS</b>                         | <b>(\$9.99)</b>  | <b>(\$5.51)</b>  | <b>(\$7.27)</b>  | <b>(\$23.44)</b>   | <b>(\$8.42)</b>  | <b>(\$5.41)</b>  | <b>(\$1.23)</b>  | <b>\$3.22</b>  | <b>\$0.66</b>  | <b>(\$0.58)</b> | <b>(\$0.17)</b> | <b>\$3.13</b>    | <b>(\$0.29)</b> | <b>(\$0.25)</b> | <b>\$0.41</b>  | <b>(\$0.07)</b> | <b>(\$0.20)</b> | <b>\$0.19</b>  |
| YoY % Chng                               |                  | 44.8%            | (31.9%)          | (222.4%)           | 64.1%            | 35.7%            | 77.3%            | 406.7%         | (39.4%)        | 23.3%           | 66.6%           | 354.2%           | (109.0%)        | (138.4%)        | 171.2%         | 57.5%           | (106.4%)        | 195.7%         |
| <b>Diluted EPS</b>                       | <b>(\$9.99)</b>  | <b>(\$5.51)</b>  | <b>(\$7.27)</b>  | <b>(\$23.44)</b>   | <b>(\$8.42)</b>  | <b>(\$5.41)</b>  | <b>(\$1.23)</b>  | <b>\$2.93</b>  | <b>\$0.62</b>  | <b>(\$0.58)</b> | <b>(\$0.17)</b> | <b>\$2.80</b>    | <b>(\$0.29)</b> | <b>(\$0.25)</b> | <b>\$0.38</b>  | <b>(\$0.07)</b> | <b>(\$0.24)</b> | <b>\$0.14</b>  |
| YoY % Chng                               |                  | 44.8%            | (31.9%)          | (222.4%)           | 64.1%            | 35.7%            | 77.3%            | 379.0%         | (37.4%)        | 23.3%           | 66.6%           | 327.4%           | (109.9%)        | (140.9%)        | 165.1%         | 57.5%           | (108.4%)        | 158.3%         |



---

## Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

### Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

### Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

---

### Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

|                |   |
|----------------|---|
| Value Score    | C |
| Growth Score   | D |
| Momentum Score | C |
| VGM Score      | D |

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

---

## Disclosures

**This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless otherwise indicated in the report's first-page footnote.** Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.